百济神州BCL-2抑制剂索托克拉片拟纳入优先审评

药事纵横
18 Apr

4月17日,中国国家药监局药品审评中心(CDE)宣布,将百济神州自主研发的新一代BCL-2抑制剂索托克拉片(Sonrotoclax)的两项适应症纳入优先审评程序。此次审评涉及的适应症包括:用于治疗既往接受过治疗的慢性淋巴细胞白血病(CLL)或小淋巴细胞淋巴瘤(SLL)成人患者;用于治疗既往接受过抗CD20治疗和BTK抑制剂(BTKi)治疗的套细胞淋巴瘤(MCL)成人患者。这一决定标志着索托克拉片在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10